AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aurobindo Pharma Leads Acquisition Race for Zentiva in $5.5 Billion Deal
ByAinvest
Wednesday, Aug 20, 2025 2:56 am ET1min read
Aurobindo Pharma is leading the race to acquire Prague-based generic drugmaker Zentiva for up to $5.5 billion from Advent International. However, the company has stated that no binding agreements have been signed by its board. The acquisition would strengthen Aurobindo Pharma's presence in the European market.
Indian pharmaceutical giant Aurobindo Pharma is in advanced negotiations to acquire Prague-based generic drugmaker Zentiva from Advent International for an estimated $5-5.5 billion. The deal, if successful, would mark the largest acquisition by an Indian pharmaceutical firm to date. Aurobindo has secured a $4.75 billion credit line from MUFG and plans to contribute approximately $800 million from internal funds [3].Zentiva operates in 30 countries with projected 2024 revenue of 1.70 billion euros and EBITDA of 400 million euros. The acquisition would significantly expand Aurobindo's presence in Eastern Europe and strengthen its position in the European generic drug market. Aurobindo's current market capitalization stands at Rs 63,684.90 crore, with its European business reporting a 16.6% increase in the June quarter [3].
The acquisition would also bolster Aurobindo's biosimilar pipeline, with the company developing robust biosimilars such as denosumab (Prolia) for osteoporosis, omalizumab (Xolair) for multiple cancer treatments, and bevacizumab (Avastin) for multiple cancer treatments. Aurobindo aims to achieve 40-60% margins in the EU biosimilar segment and aims for a blended 50% gross margin [1].
Industry watchers anticipate a formal announcement regarding the acquisition within the next two to four weeks, signaling the culmination of these high-stakes negotiations. The potential acquisition underscores Aurobindo's ambitious growth strategy and its commitment to expanding its global footprint in the pharmaceutical industry [3].
References:
[1] https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-leads-race-for-5-5-bn-zentiva-deal-set-to-be-indias-biggest-pharma-buyout/articleshow/123394210.cms
[2] https://finance.yahoo.com/news/indias-aurobindo-pharma-leads-race-065052905.html
[3] https://scanx.trade/stock-market-news/orders-deals/aurobindo-pharma-eyes-record-breaking-5-5-billion-zentiva-acquisition/17196537
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet